AHK-Cu
Cosmetic/topical hair and skin peptide; Systemic PK not established
Brief Overview: AHK-Cu is a copper-binding tripeptide used mainly in topical scalp and skin products. It is discussed for hair-follicle signaling and dermal remodeling, not for whole-body hormone effects. Evidence lens: The evidence is strongest as local cosmetic or dermatologic mechanism work. Claims about systemic regeneration or injectable hair restoration should be treated as lower-certainty unless tied to a specific clinical formulation. How to read this: if you're new, focus on formulation, concentration, pH, and irritation. Once you're past the basics, separate AHK-Cu from GHK-Cu, because the two are related copper peptides but are not interchangeable.
- AHK-Cu is L-alanyl-L-histidyl-L-lysine complexed with copper.
- It is usually grouped as a signal peptide and copper-delivery complex.
- In practical use it appears mostly in topical scalp serums, cosmetic formulations, and some provider-supervised mesotherapy contexts.
- AHK-Cu is best framed as a copper-binding tripeptide cosmetic/hair-research compound. It is close in theme to GHK-Cu but is not interchangeable with it, because sequence, target tissue, formulation, and evidence base differ.
- Proposed mechanisms include support of dermal-papilla cell activity, wound-healing signaling, angiogenic signaling around follicles, and extracellular-matrix remodeling.
- Because copper complexation is central to the molecule, formulation pH and oxidation state matter.
- The practical mechanism is local copper-peptide signaling around follicle and skin biology, not systemic endocrine action. The relevant claims center on extracellular-matrix remodeling, follicle-support hypotheses, and local tissue signaling. The mechanism here is a plausibility map, not proof of a clinical outcome.
- The most useful evidence concerns local skin/scalp biology: hair-cycle support, dermal fibroblast signaling, and cosmetic formulation behavior.
- There is no proof that AHK-Cu has systemic anti-aging effects, and blue copper-peptide products do not all share equivalent activity.
- Evidence is mainly in vitro, cosmetic, scalp/hair-oriented, or extrapolated from copper peptide biology. Human hair-growth claims need careful wording because robust, large controlled trials are not the foundation here. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Topical Scalp Serum [Topical/Cosmetic]; Route: Topical scalp; Frequency: Once or twice daily; Duration: 3 to 6 months (Minimum); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Cosmetic Formulation [Topical/Cosmetic]; Route: Topical cosmetic; Frequency: Once daily (Nightly); Duration: Indefinite; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Typical topical use-case concentrations [Topical/Cosmetic]; Route: Topical serum/scalp tonic/microneedling adjuvant; Frequency: Once or twice daily; Duration: 12-week cycles with rest periods to assess effect; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Topical and mesotherapy-style community use are separate categories. Concentration, vehicle, scalp penetration, irritation, and frequency matter more than simply naming milligrams. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: not calculable.
- Half-life basis: reliable human systemic PK for topical or mesotherapy AHK-Cu is not established. Local tissue exposure depends on formulation, pH, vehicle, barrier status, and application method.
- Beginner translation: If you're new, this means there is no honest blood-level steady-state number. Hair and skin effects, if present, are tissue-remodeling outcomes measured over weeks to months.
- Practical interpretation: Track standardized scalp photos, hair density, irritation, and product tolerance rather than trying to model systemic accumulation.
- Systemic PK is not the right lens for topical AHK-Cu. Local delivery, skin barrier penetration, copper binding, and formulation stability drive practical interpretation. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Microneedling, minoxidil, niacinamide, and GHK-Cu are common pairing discussions, but compatibility depends on timing and formulation.
- Do not combine copper peptides in the same application with strong acids such as low-pH L-ascorbic acid or aggressive AHA/BHA products unless the formulation is designed for that use.
- Comparison note: AHK-Cu is generally framed as more hair/scalp-targeted, while GHK-Cu is more broadly discussed for skin remodeling and wound-healing biology.
- That comparison is practical, not proof that one is universally superior.
- Common pairings are minoxidil, microneedling, GHK-Cu, caffeine serums, or anti-inflammatory scalp routines. Do not imply same-vial compatibility with copper peptides unless exact formulation testing exists. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Topical irritation, redness, dryness, or itching may occur, especially with high concentrations, harsh vehicles, or recent microneedling.
- Avoid use on infected or broken skin unless supervised.
- Known copper allergy or Wilson disease requires clinician review.
- Topical irritation, dermatitis, copper sensitivity, staining, and overuse are the realistic concerns. Injectable or systemic AHK-Cu claims need a much higher safety burden. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Track standardized photos, hair-shed counts, trichoscopy if available, scalp irritation, and changes in hair caliber over 8 to 12 weeks or longer.
- For systemic copper-peptide use, copper and ceruloplasmin may be relevant only under clinician supervision.
- For scalp use, track shedding, photos, irritation, dandruff/seborrhea flare, and adherence over months. Hair-cycle timing makes week-to-week conclusions unreliable. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- AHK-Cu is commonly sold as a cosmetic or research raw material. It is not an FDA-approved drug for hair loss.
- Athletes should still verify any injectable or compounded product against current anti-doping rules and product ingredients.
- AHK-Cu is generally encountered as cosmetic/RUO material rather than an approved drug. Cosmetic availability is not proof of therapeutic efficacy. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.